FORTRESS BIOTECH.PRF.A 25 Logo
US34960Q2084
A2PYCP
FBIOP

FORTRESS BIOTECH.PRF.A 25

Loading quotes...

Forecast

Buy
  10
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Fortress Biotech: subsidiary's gout drug reaches phase‑3 trials

    Fortress Biotech's stock rose about 3.3% after news that Crystalys Therapeutics' gout drug dotinurad was included in two global phase‑3 trials (RUBY and TOPAZ). The studies compare the safety and efficacy of dotinurad with allopurinol in adults with hyperuricemic and tophaceous gout. Fortress holds a minority stake in Crystalys through Urica and is entitled to a 3% royalty on future net sales. The company views the milestone as part of a series of positive business developments, including recent FDA approvals and the sale of Checkpoint Therapeutics to Sun Pharma. » More on de.investing.com


  • Fortress Biotech shares plunge after FDA rejects Menkes drug

    Fortress Biotech’s stock fell about 33.7% after the company announced the FDA issued a Complete Response Letter for CUTX-101 (copper histidinate) due to deficiencies in cGMP manufacturing. The agency raised no concerns about efficacy or safety; the manufacturing site has already submitted responses following a reinspection. Sentynl Therapeutics will request a meeting with the FDA to discuss a potential resubmission. If approved, Cyprium Therapeutics would be entitled to a Rare Pediatric Disease Priority Review Voucher and possible license and milestone payments of up to $129 million. » More on de.investing.com


  • FBI reaches settlements with agents who alleged politicization, several reinstated

    The Justice Department settled 10 cases with current and former FBI agents who said they were disciplined for expressing political views or clashing with supervisors, with three agents returning to duty and others allowed to retire or receive back pay. Empower Oversight announced the resolutions, which follow Republican accusations that the FBI politicized investigations during the Biden administration and come amid recent reassignments and dismissals under Director Kash Patel. Some reinstated agents named include Steve Friend, Garret O'Boyle and Zachery Schoffstall; one earlier settlement restored Marcus Allen’s clearance. » More on yahoo.com

Historical dividends Dividends

All dividend metrics All metrics
In 2024, FORTRESS BIOTECH.PRF.A 25 has already paid €1.08 in dividends. The last payout was in June 2024.

Financials

In the last quarter, FORTRESS BIOTECH.PRF.A 25 had revenue of €16.91M and net profit of -€5.16M
(EUR) September 2026
YoY
Revenue 16.91M 12.58%
Gross profit 11.72M 15.81%
Net profit -5.16M 203.52%
EBITDA -4.19M 139.57%

Fundamentals

Metric Value
Market capitalization
€53.73M
Number of shares
4.12M
52-week high/low
€19.47 - €5.90
Dividends No
Beta
1.21
P/E ratio
0.65
PEG ratio
0.00
P/B ratio
0.40
P/S ratio
0.90

Company profile

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Name
FORTRESS BIOTECH.PRF.A 25
CEO
Lindsay A. Rosenwald
Headquarters Bay Harbor Islands, fl
USA
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
11/14/2017
Employees 78

Ticker symbols

Exchange Symbol
NASDAQ
FBIOP
🍪

Parqet  uses cookies. Learn more